drugset / Trial / NCT06481085

To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

NCT06481085

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a randomized, double-blind, placebo controlled, parallel group study, which aims to provide data on efficacy, safety and pharmacokinetics (PK) of multiple dose levels of HDM1002 tablets in adults with type 2 diabetes mellitus (T2DM) inadequately controlled on metformin and/or diet and exercise.

Timeline

Start
2024-06-27
Primary completion
2025-05-30
Completion
2025-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject HDM1002 Unknown 50 mg Oral
Subject HDM1002 Unknown 100 mg Oral
Subject HDM1002 Unknown 200 mg Oral
Subject HDM1002 Unknown 400 mg Oral